Consonance-Hfw Acq Corp (SRZN) Stock Price, Quote & News

Company Profile

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat di...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 489 9000

Website: www.surrozen.com

Address:

171 Oyster Point Boulevard, Suite 400, South San Francisco, United States

Phaaisatroll Oct. 3 at 8:18 PM

$SRZN new interview with our CEO talking about Surrozen and M&A deals. Interesting choice that topic. https://www.linkedin.com/pulse/biotech-leader-spotlight-series-partnology-nnu8c?utm_source=share&utm_medium=member_android&utm_campaign=share_via

0 · Reply

Jw242 Oct. 3 at 4:03 PM

$SRZN wife offered multiple hummers this weekend if this finishes above $14 🤞🍒

1 · Reply

raticals Oct. 2 at 2:13 PM

$SRZN I guess we won’t know until they do some sort of SEC filing probably with their quarterly earnings. But reading by opting out of the lease it’ll save them over $7 million over the next three years. It’ll cost 400,000 to bust the lease they could easily then move into the space that the other column group has in the same building

2 · Reply

raticals Oct. 1 at 2:31 PM

$SRZN

2 · Reply

Phaaisatroll Oct. 1 at 4:19 AM

$SRZN up 10% on the last potential day of their lease termination. Is that a sign or just a pump from tutes who want to sell as high as possible?

0 · Reply

raticals Sep. 30 at 7:35 PM

$SRZN 😆😆😆😆😆😆😆

1 · Reply

AstraCrownFunds Sep. 30 at 7:28 PM

$SRZN SHOT Micro-cap + improving balance sheet + momentum tape = chef’s kiss. Targeting .30 before the bell. 🍽️📈

0 · Reply

Jw242 Sep. 30 at 7:17 PM

$SRZN pumpers showing up eh ?

1 · Reply

GoldenBayAssets Sep. 30 at 6:46 PM

$SRZN

1 · Reply

jo4vie_brock Sep. 30 at 6:18 PM

$SRZN Tape keeps ticking 0.2740–0.2750 in green, buyers push toward HOD on $SHOT ⚡️

0 · Reply

Surrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 3, 2025, 4:15 PM EDT - 4 weeks ago

Surrozen to Present at Upcoming Healthcare Investor Conference

Aug 8, 2025, 4:05 PM EDT - 2 months ago

Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update

May 14, 2025, 8:30 AM EDT - 5 months ago

Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway

May 9, 2025, 4:05 PM EDT - 5 months ago

Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update

Mar 31, 2025, 4:05 PM EDT - 6 months ago

Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Mar 24, 2025, 9:00 AM EDT - 6 months ago

Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases

Nov 6, 2024, 4:30 PM EST - 11 months ago

Surrozen to Present at Upcoming Healthcare Investor Conferences

Nov 6, 2024, 9:00 AM EST - 11 months ago

Surrozen Provides Third Quarter 2024 Financial Results and Business Update

Nov 4, 2024, 8:30 AM EST - 11 months ago

Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis

Sep 24, 2024, 8:30 AM EDT - 1 year ago

Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration

Aug 12, 2024, 4:05 PM EDT - 1 year ago

Surrozen Provides Second Quarter 2024 Financial Results and Business Update

Jun 12, 2024, 8:30 AM EDT - 1 year ago

Surrozen Publishes Study in ‘eLife' Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling

Jun 10, 2024, 8:30 AM EDT - 1 year ago

Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan

Jun 4, 2024, 8:30 AM EDT - 1 year ago

Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis

May 9, 2024, 8:30 AM EDT - 1 year ago

Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting

May 8, 2024, 4:05 PM EDT - 1 year ago

Surrozen Provides First Quarter 2024 Financial Results and Business Update

Apr 3, 2024, 8:40 AM EDT - 1 year ago

Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis

Apr 1, 2024, 8:30 AM EDT - 1 year ago

Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043

Apr 1, 2024, 8:30 AM EDT - 1 year ago

Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules

Jan 18, 2024, 8:30 AM EST - 1 year ago

Surrozen Provides Corporate Update on Clinical Programs

Nov 8, 2023, 4:05 PM EST - 2 years ago

Surrozen Provides Third Quarter 2023 Financial Results

Aug 9, 2023, 4:05 PM EDT - 2 years ago

Surrozen Provides Second Quarter 2023 Financial Results

Jun 5, 2023, 8:30 AM EDT - 2 years ago

Surrozen Publishes Study in Nature Communications Demonstrating the Promise of a Fzd4 Wnt Antibody in Treating Ischemic Stroke

May 10, 2023, 4:05 PM EDT - 2 years ago

Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates

Apr 5, 2023, 8:30 AM EDT - 2 years ago

Surrozen Strengthens Board of Directors with the Appointment of Eric Bjerkholt

Mar 25, 2023, 10:02 AM EDT - 2 years ago

Surrozen, Inc. (SRZN) Q4 2022 Earnings Call Transcript

Mar 22, 2023, 4:01 PM EDT - 2 years ago

Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress

Mar 20, 2023, 4:30 PM EDT - 2 years ago

Surrozen To Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 22, 2023

Jan 4, 2023, 4:41 PM EST - 2 years ago

Surrozen to Present at the 41st Annual J.P. Morgan Healthcare Conference

Nov 14, 2022, 4:30 PM EST - 3 years ago

Surrozen Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Oct 10, 2022, 8:00 AM EDT - 3 years ago

Surrozen Presents Data on Two Lead Therapeutic Candidates at United European Gastroenterology (UEG) Week

Oct 6, 2022, 8:00 AM EDT - 3 years ago

Surrozen Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt Agonist SZN-413 for People with Retinal Diseases

Sep 26, 2022, 8:00 AM EDT - 3 years ago

Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of SZN-413 in Preclinical Models of Diabetic Retinopathy

Aug 11, 2022, 8:00 AM EDT - 3 years ago

Surrozen Reports Second Quarter 2022 Financial Results

Jun 13, 2022, 8:00 AM EDT - 3 years ago

Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis

May 24, 2022, 8:00 AM EDT - 3 years ago

Surrozen Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)

May 18, 2022, 8:00 AM EDT - 3 years ago

Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis

May 16, 2022, 8:00 AM EDT - 3 years ago

Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology Demonstrating that SZN-1326, a Selective Wnt Mimetic, Stimulated Robust Colon Epithelial Regeneration and Ameliorated Colitis in an Acute Model of Inflammatory Bowel Dise

May 11, 2022, 8:00 AM EDT - 3 years ago

Surrozen Reports First Quarter 2022 Financial Results

May 5, 2022, 8:00 AM EDT - 3 years ago

Surrozen to Present at the BofA Securities 2022 Healthcare Conference

May 2, 2022, 8:00 AM EDT - 3 years ago

Surrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Mar 24, 2022, 8:00 AM EDT - 3 years ago

Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results

Jan 10, 2022, 8:00 AM EST - 4 years ago

Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline

Jan 5, 2022, 8:00 AM EST - 4 years ago

Surrozen to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference

Nov 15, 2021, 4:00 PM EST - 4 years ago

Surrozen Reports Third Quarter 2021 Financial Results

Nov 15, 2021, 8:00 AM EST - 4 years ago

Surrozen to Present at The Piper Sandler 33rd Annual Healthcare Conference

Nov 15, 2021, 8:00 AM EST - 4 years ago

Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Meeting 2021, the Annual Meeting of the American Association for the Study of Liver Diseases

Nov 5, 2021, 8:00 AM EDT - 4 years ago

Surrozen to Present at The Stifel 2021 Virtual Healthcare Conference

Oct 6, 2021, 7:17 AM EDT - 4 years ago

Surrozen's Inflammatory Bowel Disease Candidate Shows Encouraging Preclinical Action

Phaaisatroll Oct. 3 at 8:18 PM

0 · Reply

Jw242 Oct. 3 at 4:03 PM

$SRZN wife offered multiple hummers this weekend if this finishes above $14 🤞🍒

1 · Reply

raticals Oct. 2 at 2:13 PM

2 · Reply

raticals Oct. 1 at 2:31 PM

$SRZN

2 · Reply

Phaaisatroll Oct. 1 at 4:19 AM

$SRZN up 10% on the last potential day of their lease termination. Is that a sign or just a pump from tutes who want to sell as high as possible?

0 · Reply

raticals Sep. 30 at 7:35 PM

$SRZN 😆😆😆😆😆😆😆

1 · Reply

AstraCrownFunds Sep. 30 at 7:28 PM

$SRZN SHOT Micro-cap + improving balance sheet + momentum tape = chef’s kiss. Targeting .30 before the bell. 🍽️📈

0 · Reply

Jw242 Sep. 30 at 7:17 PM

$SRZN pumpers showing up eh ?

1 · Reply

GoldenBayAssets Sep. 30 at 6:46 PM

$SRZN

1 · Reply

jo4vie_brock Sep. 30 at 6:18 PM

$SRZN Tape keeps ticking 0.2740–0.2750 in green, buyers push toward HOD on $SHOT ⚡️

0 · Reply

raticals Sep. 30 at 5:49 PM

$SRZN I’ll crap all over myself if they break their lease 😆😆😆

1 · Reply

Jw242 Sep. 30 at 5:49 PM

$SRZN 65k buy and we drop. Classic

0 · Reply

Phaaisatroll Sep. 30 at 11:52 AM

$SRZN Surrozen is going to this conference: https://www.instagram.com/reel/DPMuMAekuYn/ https://www.eyecelerator.com/

0 · Reply

Jw242 Sep. 29 at 7:53 PM

$SRZN so confused.

1 · Reply

phaa Sep. 26 at 5:23 PM

$SRZN I see Phaaisatroll has moved on to this ticker to spread his expertize.

0 · Reply

raticals Sep. 25 at 8:05 PM

$SRZN chalk it up in things I’ll never understand. Average volume is 15k. 60k makes it trade in band of .15-.20 cents, but a 6k day makes it trade .75-1.00.

1 · Reply

raticals Sep. 25 at 3:37 PM

$SRZN I know this is a big-time longshot, but if they terminate their lease, which they have the right to do by the end of the month, do they have to make a filing on that. How will we know. Because if they do, I will put significant amount of money into this.

1 · Reply

Jw242 Sep. 24 at 3:01 PM

$SRZN what a joke. 75k shares move us well above $12. And less then a few thousand to take us right back down

0 · Reply

highnihilism Sep. 24 at 1:26 PM

Market cap ≤ $500M (Unusual Volume, Biotech) $BIVI BioVie $INVO Invo Bioscience $KRON Kronos Bio $MRSN Mersana Therapeutics $SRZN Surrozen

0 · Reply

raticals Sep. 23 at 4:20 PM

$SRZN if this stock was close to being liquid I would buy big here.

1 · Reply

Phaaisatroll Sep. 23 at 2:31 PM

$SRZN what could happen if Restoret is infriging our patents?

1 · Reply

Jw242 Sep. 22 at 1:48 PM

$SRZN the manipulation runs so deep here 🤷

1 · Reply

Market Cap	117.29M
Revenue (ttm)	10.66M
Net Income (ttm)	-63.56M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-596.25%
Debt to Equity Ratio	0.00

Volume	6,700
Avg Vol	18,188
Day's Range	N/A - N/A
Shares Out	8.57M
Stochastic %K	92%
Beta	0.63
Analysts	Strong Sell
Price Target	$37.00